Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia

Blood Adv. 2019 Jun 25;3(12):1891-1896. doi: 10.1182/bloodadvances.2018030262.

Abstract

  1. Microenvironmental stimuli affect EZH2 expression and function in CLL.

  2. Combined B-cell signaling and EZH2 inhibition showed synergistic effects on primary CLL cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Apoptosis / drug effects
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / metabolism
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Down-Regulation / drug effects
  • Drug Synergism
  • Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors*
  • Enhancer of Zeste Homolog 2 Protein / drug effects
  • Enhancer of Zeste Homolog 2 Protein / metabolism
  • Enzyme Inhibitors / pharmacology
  • Histones / drug effects
  • Humans
  • Indazoles / pharmacology
  • Indoles / pharmacology
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • Piperidines
  • Purines / pharmacology
  • Pyrazoles / pharmacology
  • Pyridones / pharmacology
  • Pyrimidines / pharmacology
  • Quinazolinones / pharmacology
  • Signal Transduction / drug effects*
  • Sulfonamides / pharmacology
  • Tumor Microenvironment / drug effects

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Enzyme Inhibitors
  • GSK-2816126
  • GSK343
  • Histones
  • Indazoles
  • Indoles
  • Piperidines
  • Purines
  • Pyrazoles
  • Pyridones
  • Pyrimidines
  • Quinazolinones
  • Sulfonamides
  • ibrutinib
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Adenine
  • venetoclax
  • idelalisib